Mode
Text Size
Log in / Sign up
Phase 3 Completed N=3,506 Randomized Single-blind Treatment

Myocardial Ischemia and Transfusion

Source: ClinicalTrials.gov NCT02981407 ↗
Enrolled (actual)
3,506
Serious AEs
40.6%
Results posted
May 2024
Primary outcomePrimary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants
◆ Published Evidence
Emerging
9citations · ~9 / year
Transfusion thresholds and other strategies for guiding red blood cell transfusion.
The Cochrane database of systematic reviews · 2025 · Open access · Likely link

Summary

The purpose of this study is to compare two red blood cell transfusion strategies (liberal and restrictive) for patients who have had an acute myocardial infarction and are anemic.

Linked Publications (5)

  • Transfusion thresholds and other strategies for guiding red blood cell transfusion.
    The Cochrane database of systematic reviews · 2025 · 9 citations · Open access · Likely link
  • Transfusion Strategy Effect on Quality of Life in Patients With Myocardial Infarction and Anemia: A Secondary Analysis of the MINT Randomized Clinical Trial.
    JAMA internal medicine · 2025 · 5 citations · Open access · Likely link
  • Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial.
    Circulation. Cardiovascular interventions · 2025 · 2 citations · Open access · Likely link
  • Comparative Efficacy of Transfusion Strategies in Women and Men With Myocardial Infarction and Anemia: Prespecified Secondary Findings From the MINT Trial.
    Circulation · 2026 · 0 citations · Likely link
  • Effect of age on restrictive and liberal transfusion outcomes in patients with anemia and myocardial infarction.
    American heart journal · 2026 · 0 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction
255; 295
SECONDARY
All-cause Mortality
SECONDARY
Myocardial Reinfarction
126; 149
SECONDARY
Composite of All-cause Mortality, Nonfatal Myocardial Reinfarction, Ischemia Driven Unscheduled Coronary Revascularization, or Readmission to the Hospital for Ischemic Cardiac Diagnosis
305; 342

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Either ST segment elevation myocardial infarction or Non ST segment elevation myocardial infarction consistent with the 3rd Universal Definition of Myocardial Infarction criteria that occurs on admission or during the index hospitalization
  • Hemoglobin concentration less than 10 g/dL at the time of random allocation
  • Patient physician believes that both of the transfusion strategies are consistent with good medical care for the patient

Exclusion Criteria

  • Uncontrolled acute bleeding at the time of randomization defined as the need for uncrossed or non-type specific blood
  • Decline blood transfusion
  • Scheduled for cardiac surgery during the current admission
  • Receiving only palliative treatment
  • Known that follow-up will not be possible at 30 days
  • Previously participated in MINT
  • Currently enrolled in a competing study that interferes with the intervention or follow-up of MINT or enrolled in a competing study that has not been approved by the local Institutional Review Board
  • Patient physician does not believe the patient is an appropriate candidate for the trial
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02981407) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search